Anti-CD38 Monoclonal Antibody SCTC21C clinical trials
Also written SCTC21C.
Its developmentBy Sinocelltech Group, step by step5 company-led studies, furthest phase 3: when each phase was reached, its deals, target and what is ahead.How each study uses Anti-CD38 Monoclonal Antibody SCTC21C is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Anti-CD38 Monoclonal Antibody SCTC21C studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- SCTC21C
- 5
Studies by the year they started
5 studies that test it; most in 2025 (2)
| Year | Studies |
|---|---|
| 2024 | 1 |
| 2025 | 2 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 0
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 2
Studies that test Anti-CD38 Monoclonal Antibody SCTC21C.
- Apr 2027A Clinica Study of SCTC21C in Participants With Systemic Lupus ErythematosusPhase 1/2 · Sinocelltech Ltd.
- Sep 2027A Clinical Study of SCTC21C in Participants With Plasma Cell-driven Autoimmune DiseasesPhase 1/2 · Sinocelltech Ltd.
Studies
Open first, then newest update. How each study uses Anti-CD38 Monoclonal Antibody SCTC21C is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- A Clinica Study of SCTC21C in Participants With Systemic Lupus ErythematosusNot yet recruitingPhase 1/2Sinocelltech Ltd.NCT07538154Written as SCTC21C
- A Study to Evaluate the Safety and Efficacy of SCTC21C in Combination With Bortezomib, Cyclophosphamide, and Dexamethasone in Patients With Newly Diagnosed Systemic Light-Chain Amyloidosis (NDSLCA)RecruitingPhase 3Sinocelltech Ltd.NCT07388602Written as SCTC21C
- A Study to Evaluate the Safety and Efficacy of SCTC21C in Combination With Bortezomib, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Not Eligible for TransplantRecruitingPhase 3Sinocelltech Ltd.NCT07297329Written as SCTC21C
- A Clinical Study of SCTC21C in Participants With Plasma Cell-driven Autoimmune DiseasesNot yet recruitingPhase 1/2Sinocelltech Ltd.NCT06774664Written as SCTC21C
- A Clinical Study of SCTC21C in Participants With CD38+ Hematologic MalignanciesRecruitingPhase 1Sinocelltech Ltd.NCT06252298Written as SCTC21C